Organon (OGN) Intangibles (2020 - 2026)
Organon (OGN) posted quarterly Intangibles of $1.1 billion for Q2 2026, down 18.36% year-over-year from $1.4 billion in Q2 2025, and up 1.18% on a QoQ basis from $1.1 billion in Q1 2026.
Organon (OGN) Intangibles (2020 - 2026) Analysis & Trends
Organon has reported Intangibles for 7 years, with the latest figure at $1.1 billion in Q2 2026.
- Intangibles for Q2 2026 came in at $1.1 billion, down 18.36% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.1 billion (down 18.36% YoY), and the FY2025 annual result was $1.1 billion, down 20.08% from the prior year.
- Intangibles grew to $1.1 billion in Q2 2026, from $1.1 billion in the prior quarter.
- Over five years, Intangibles peaked at $24.5 billion in Q4 2023 and troughed at $30.0 million in Q3 2025.
- A 5-year average of $2.0 billion and a median of $657.0 million in 2022 frame the typical range for Intangibles.
- The widest annual swing landed in 2023, when Intangibles soared 3678.27%; it then tumbled 94.23% in 2024.
- A 5-year view of Intangibles shows it stood at $649.0 million in 2022, then soared by 3678.27% to $24.5 billion in 2023, then tumbled by 94.23% to $1.4 billion in 2024, then dropped by 20.08% to $1.1 billion in 2025, then retreated by 1.59% to $1.1 billion in 2026.
- Per Business Quant data, the three most recent Intangibles figures were $1.1 billion in Q2 2026, $1.1 billion in Q1 2026, and $1.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 48.23 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 49.14 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 24.98 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 42.07 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 37.72 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 20.49 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 14.03 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 47.05 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 22.54 Bn |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn | 1.11 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.11 Bn |
| Mar 31, 2026 | 1.10 Bn |
| Dec 31, 2025 | 1.13 Bn |
| Sep 30, 2025 | 30.00 Mn |
| Jun 30, 2025 | 1.36 Bn |
| Mar 31, 2025 | 51.00 Mn |
| Dec 31, 2024 | 1.41 Bn |
| Sep 30, 2024 | 113.00 Mn |
| Jun 30, 2024 | 684.00 Mn |
| Mar 31, 2024 | 220.00 Mn |
| Dec 31, 2023 | 533.00 Mn |
| Sep 30, 2023 | 561.00 Mn |
| Jun 30, 2023 | 592.00 Mn |
| Mar 31, 2023 | 621.00 Mn |
| Dec 31, 2022 | 649.00 Mn |
| Sep 30, 2022 | 670.00 Mn |
| Jun 30, 2022 | 638.00 Mn |
| Mar 31, 2022 | 665.00 Mn |
| Dec 31, 2021 | 651.00 Mn |
| Sep 30, 2021 | 683.00 Mn |